StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

NASDAQ:BPTH opened at $0.16 on Friday. Bio-Path has a 12-month low of $0.12 and a 12-month high of $7.67. The firm has a 50-day moving average price of $0.28 and a 200 day moving average price of $0.70.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.